Blair William & Co. IL Reduces Stock Position in OptimizeRx Co. (NASDAQ:OPRX)

Blair William & Co. IL lessened its position in OptimizeRx Co. (NASDAQ:OPRX - Free Report) by 11.2% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 601,383 shares of the company's stock after selling 75,711 shares during the period. Blair William & Co. IL owned 3.26% of OptimizeRx worth $2,923,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. BNP Paribas Financial Markets lifted its holdings in OptimizeRx by 189.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company's stock worth $28,000 after buying an additional 2,414 shares during the period. Perkins Capital Management Inc. boosted its holdings in OptimizeRx by 4.4% in the fourth quarter. Perkins Capital Management Inc. now owns 105,813 shares of the company's stock valued at $514,000 after acquiring an additional 4,450 shares in the last quarter. SBI Securities Co. Ltd. bought a new stake in OptimizeRx in the fourth quarter valued at $25,000. SG Americas Securities LLC purchased a new position in OptimizeRx during the 4th quarter valued at $51,000. Finally, Barclays PLC raised its holdings in OptimizeRx by 358.5% in the 3rd quarter. Barclays PLC now owns 26,934 shares of the company's stock worth $208,000 after purchasing an additional 21,060 shares in the last quarter. Hedge funds and other institutional investors own 76.47% of the company's stock.

Insider Buying and Selling

In other news, Director James Paul Lang bought 321,408 shares of the company's stock in a transaction dated Friday, March 14th. The shares were purchased at an average price of $7.60 per share, for a total transaction of $2,442,700.80. Following the completion of the purchase, the director now owns 389,452 shares in the company, valued at approximately $2,959,835.20. This represents a 472.35 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 6.10% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

OPRX has been the topic of a number of research reports. Royal Bank of Canada reaffirmed a "sector perform" rating and set a $6.00 target price (down previously from $7.00) on shares of OptimizeRx in a research note on Wednesday, January 8th. Stephens assumed coverage on OptimizeRx in a report on Friday, December 20th. They set an "equal weight" rating and a $5.50 target price on the stock. JMP Securities restated a "market outperform" rating and issued a $8.00 target price on shares of OptimizeRx in a research note on Thursday, February 6th. Lake Street Capital reaffirmed a "buy" rating and issued a $11.00 price target on shares of OptimizeRx in a research note on Tuesday, December 24th. Finally, B. Riley raised OptimizeRx to a "strong-buy" rating in a research report on Wednesday, March 12th. Three research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, OptimizeRx has a consensus rating of "Moderate Buy" and an average price target of $9.06.

OptimizeRx Stock Down 1.6 %

OptimizeRx stock traded down $0.13 during mid-day trading on Friday, hitting $7.75. The company had a trading volume of 311,919 shares, compared to its average volume of 264,898. OptimizeRx Co. has a 12 month low of $3.78 and a 12 month high of $14.13. The company has a market capitalization of $143.30 million, a PE ratio of -5.83 and a beta of 1.18. The stock's 50 day moving average price is $6.53 and its two-hundred day moving average price is $6.00. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 0.29.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.